AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12949809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco chewing
Number of subjects: 115
Study 12949809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco chewing frequency
Number of subjects: 115
Study 12949809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco chewing duration
Number of subjects: 115
Study 12949809 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 115
Study 12949809 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 115
Study 10804488 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical estimates
Number of subjects: 758
Study 10804488 — intervention group
Group type: COMPARATOR
Intervention: Sonographic estimates
Number of subjects: 758
Study 8891854 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional plus L-dopa treatment
Number of subjects: 20
Study 8891854 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 20
Study 1828840 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 122
Study 1828840 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 122
Study 6517125 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal disinfection regimen for the lens on the right eye
Number of subjects: 8
Study 6517125 — intervention group
Group type: COMPARATOR
Intervention: Chemical disinfection regimen for the lens on the left eye
Number of subjects: 8
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU) in self-etch mode (SE) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond Elect (PBE) in self-etch mode (SE) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond Universal (ABU) in self-etch mode (SE) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Universal (IBU) in self-etch mode (SE) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU) in etch-and-rinse mode (ER) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond Elect (PBE) in etch-and-rinse mode (ER) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond Universal (ABU) in etch-and-rinse mode (ER) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Universal (IBU) in etch-and-rinse mode (ER) before thermocycling (TC)
Number of subjects: 360
Study 30799475 — intervention group
Group type: COMPARATOR
Intervention: Optibond FL (OFL) as etch-and-rinse control
Number of subjects: 360
Study 30799475 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Universal (IBU) in self-etch mode (SE) after thermocycling (TC)
Number of subjects: 360
Study 30935071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 66
Study 30935071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 66
Study 30935071 — intervention group
Group type: COMPARATOR
Intervention: Control (arts/crafts activities)
Number of subjects: 66
Study 28750109 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia-ceramic (ZC) fixed dental prostheses
Number of subjects: 58
Study 28750109 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic (MC) fixed dental prostheses
Number of subjects: 58
Study 26213789 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Approach Therapy (SAT)
Number of subjects: 57
Study 26213789 — intervention group
Group type: COMPARATOR
Intervention: PTSD Family Education (PFE)
Number of subjects: 57
Study 23228924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline treatment
Number of subjects: 42
Study 21971213 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 15 mg (Anesiva 4975) instillation
Number of subjects: 14
Study 21971213 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle instillation
Number of subjects: 14
Study 18273636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track treatment arm
Number of subjects: 82
Study 18273636 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment arm
Number of subjects: 82
Study 16603986 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, culturally sensitive, post-Caesarean breastfeeding guidance and education by trained professionals (n=306)
Number of subjects: 570
Study 16603986 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care (n=264)
Number of subjects: 570
Study 12924536 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg daily)
Number of subjects: 30
Study 12924536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10846912 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg
Number of subjects: 96
Study 10846912 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 96
Study 10846912 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg/kg
Number of subjects: 96
Study 10846912 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 96
Study 9442546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 18
Study 9442546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 18
Study 9442546 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine and Clomipramine
Number of subjects: 18
Study 8448974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous [14C]omeprazole 20mg
Number of subjects: 8
Study 8448974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution [14C]omeprazole 40mg
Number of subjects: 8
Study 8448974 — intervention group
Group type: COMPARATOR
Intervention: Young healthy volunteers (control group)
Number of subjects: 8
Study 2431021 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (8 to 21 micrograms/ml)
Number of subjects: 10
Study 2431021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31603033 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Regime 1 (TR1)
Number of subjects: 0
Study 31603033 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Regime 2 (TR2)
Number of subjects: 0
Study 31603033 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 31754687 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (25:45:30% energy from protein:carbohydrate:fat)
Number of subjects: 38
Study 31754687 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein (MP) diet (15:55:30% energy from protein:carbohydrate:fat)
Number of subjects: 38
Study 29886466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 200
Study 29886466 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-dimensional radiotherapy
Number of subjects: 200
Study 27501629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner‐facilitated chronic kidney disease group visit (GV) model
Number of subjects: 30
Study 27501629 — intervention group
Group type: COMPARATOR
Intervention: Usual nephrology care
Number of subjects: 30
Study 1385147 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy for BPH
Number of subjects: 66
Study 1385147 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study 1385147 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug trial
Number of subjects: 66
Study 22809684 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting injection (RLAI)
Number of subjects: 22
Study 22809684 — intervention group
Group type: COMPARATOR
Intervention: Oral risperidone (RisO)
Number of subjects: 22
Study 20406256 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometer
Number of subjects: 120
Study 20406256 — intervention group
Group type: COMPARATOR
Intervention: Non-contact tonometers (Topcon CT80 and Keeler Pulsair EasyEye)
Number of subjects: 120
Study 18712214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Training
Number of subjects: 20
Study 18712214 — intervention group
Group type: COMPARATOR
Intervention: Normal Training
Number of subjects: 20
Study 15964686 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo (GEXP)
Number of subjects: 8
Study 12690999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 144
Study 12690999 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary essential oil
Number of subjects: 144
Study 12690999 — intervention group
Group type: COMPARATOR
Intervention: Control (no odor)
Number of subjects: 144
Study 10496259 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 64
Study 10496259 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 9114899 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from standardized patients (SPs)
Number of subjects: 120
Study 9114899 — intervention group
Group type: COMPARATOR
Intervention: Feedback from faculty
Number of subjects: 120
Study 1813168 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) and clomiphene
Number of subjects: 149
Study 1813168 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 149
Study 1813168 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 149
Study 6994779 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 3.5 mg daily
Number of subjects: 20
Study 6994779 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 1.2 g daily
Number of subjects: 20
Study 30866859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with print educational materials and Fitbit Flex™ and daily text messages
Number of subjects: 42
Study 30866859 — intervention group
Group type: COMPARATOR
Intervention: Control with print educational materials alone
Number of subjects: 42
Study 28851337 — intervention group
Group type: EXPERIMENTAL
Intervention: Education module only
Number of subjects: 189
Study 28851337 — intervention group
Group type: EXPERIMENTAL
Intervention: Email prompt only
Number of subjects: 189
Study 28851337 — intervention group
Group type: EXPERIMENTAL
Intervention: Email prompt and education module
Number of subjects: 189
Study 28851337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education module and no email prompt)
Number of subjects: 189
Study 26482019 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised WINGS
Number of subjects: 191
Study 26482019 — intervention group
Group type: COMPARATOR
Intervention: Case Manager WINGS
Number of subjects: 191
Study 23564001 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic Union Score for Hip (RUSH)
Number of subjects: 150
Study 23564001 — intervention group
Group type: COMPARATOR
Intervention: Subjective assessment of overall healing
Number of subjects: 150
Study 17625632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental training
Number of subjects: 41
Study 17625632 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 41
Study 16036033 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 16036033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 16036033 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT alone or in conjunction with an ICD
Number of subjects: 0
Study 11059947 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-MDI (fenoterol hydrobromide, 100 microg, two puffs, four times a day)
Number of subjects: 290
Study 11059947 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI (fenoterol hydrobromide, 100 microg, two puffs, four times a day)
Number of subjects: 290
Study 11059947 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-MDI
Number of subjects: 290
Study 11059947 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI
Number of subjects: 290
Study 9292565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone membrane
Number of subjects: 20
Study 9292565 — intervention group
Group type: COMPARATOR
Intervention: Cellulose membrane
Number of subjects: 20
Study 8039761 — intervention group
Group type: EXPERIMENTAL
Intervention: Erwinia L-asparaginase
Number of subjects: 10
Study 8039761 — intervention group
Group type: COMPARATOR
Intervention: E. Coli L-asparaginase
Number of subjects: 10
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (n = 354)
Number of subjects: 820
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula (n = 320)
Number of subjects: 820
Study 3090512 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk (n = 146)
Number of subjects: 820
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula or human milk (younger subjects)
Number of subjects: 820
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: All milk feeding groups (40 infants 8 to 12 months)
Number of subjects: 820
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: All milk feeding groups (792 stool smears)
Number of subjects: 820
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: All milk feeding groups (705 stool smears)
Number of subjects: 820
Study 3090512 — intervention group
Group type: EXPERIMENTAL
Intervention: All infants
Number of subjects: 820
Study 31828137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified regimen (higher dosage of cefoxitin and linezolid, along with conventional drugs)
Number of subjects: 50
Study 31828137 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (including macrolide and moxifloxacin, initial 12-week course of low-dose cefoxitin and amikacin)
Number of subjects: 50
Study 30574354 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPWISE intervention (lifestyle intervention for weight management)
Number of subjects: 0
Study 30574354 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPWISE intervention
Number of subjects: 0
Study 26867764 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2 iv q 3 weeks)
Number of subjects: 25
Study 24564266 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (50 μg/ml) at an infusion rate of 0.07 μg/kg/min with bolus doses of 0.25 μg/kg and a 5‐min lockout time
Number of subjects: 50
Study 24564266 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (50 μg/ml) at an infusion rate of 0.1 μg/kg/min with bolus doses of 1 μg/kg and a 5‐min lockout time
Number of subjects: 50
Study 24564266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Remifentanil and Fentanyl)
Number of subjects: 50
Study 22812672 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tigecycline (100 mg, then 50 mg q12h)
Number of subjects: 294
Study 22812672 — intervention group
Group type: COMPARATOR
Intervention: IV levofloxacin (500 mg q24h)
Number of subjects: 294
Study 19954405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained release mucoadhesive nystatin tablets
Number of subjects: 12
Study 19954405 — intervention group
Group type: COMPARATOR
Intervention: Commercial oral nystatin suspension
Number of subjects: 12
Study 17998981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes certificate program (elective course)
Number of subjects: 37
Study 17998981 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elective course)
Number of subjects: 37
Study 16353657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling intervention
Number of subjects: 430
Study 16353657 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 430
Study 12216559 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer (GI)
Number of subjects: 45
Study 12216559 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (RMGI)
Number of subjects: 45
Study 12216559 — intervention group
Group type: COMPARATOR
Intervention: Resin composite (C)
Number of subjects: 45
Study 10221490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 83
Study 10221490 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 83
Study 7531132 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 brachytherapies with a dose of 3.8 Gy on a weekly basis (Group 1)
Number of subjects: 93
Study 7531132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 treatments with 7.2 Gy at a 3-week interval (Group 2)
Number of subjects: 93
Study 2145872 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐h‐ANP infusion (50 ng/kg/min over 1 h after a bolus of 50 micrograms)
Number of subjects: 8
Study 2145872 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 340331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 60
Study 340331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31121285 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS over the right inferior frontal gyrus
Number of subjects: 57
Study 31121285 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 57
Study 28364853 — intervention group
Group type: EXPERIMENTAL
Intervention: Affirmative writing interventions
Number of subjects: 0
Study 28364853 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25675060 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-endoscopic interlaminar technique (FI)
Number of subjects: 135
Study 25675060 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical laminotomy technique (MI)
Number of subjects: 135
Study 23651756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 20
Study 23651756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21870913 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning through challenging visual tasks
Number of subjects: 0
Study 21870913 — intervention group
Group type: EXPERIMENTAL
Intervention: Training protocols targeting stereo acuity deficits
Number of subjects: 0
Study 19674806 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/day (n=19)
Number of subjects: 50
Study 19674806 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 850 mg/day (n=16)
Number of subjects: 50
Study 19674806 — intervention group
Group type: COMPARATOR
Intervention: MNT alone (n=15)
Number of subjects: 50
Study 17405972 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 10739
Study 17405972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 17405972 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 10739
Study 15283218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral preservative-free 1% xylocaine
Number of subjects: 106
Study 15283218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 11217909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril for 4 weeks in subjects with genotype II
Number of subjects: 20
Study 11217909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril for 4 weeks in subjects with genotype DD
Number of subjects: 20
Study 11217909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril for 4 weeks in subjects with genotype II and DD
Number of subjects: 20
Study 9763048 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with a 4-hour action line
Number of subjects: 928
Study 9763048 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with a 2-hour action line
Number of subjects: 928
Study 9763048 — intervention group
Group type: COMPARATOR
Intervention: Partogram with a 3-hour action line
Number of subjects: 928
Study 7871964 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 20
Study 3277400 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal anti-T cell antibody
Number of subjects: 34
Study 3277400 — intervention group
Group type: COMPARATOR
Intervention: Triple immunosuppression (cyclosporine, azathioprine, prednisone)
Number of subjects: 34
Study 29665351 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day)
Number of subjects: 34
Study 29665351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27296086 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight (HW) intervention
Number of subjects: 58
Study 27296086 — intervention group
Group type: COMPARATOR
Intervention: Control group (HPV vaccination awareness intervention)
Number of subjects: 58
Study 26713528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UTI (16000 U/kg i.v.)
Number of subjects: 127
Study 26713528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose UTI (8000 U/kg i.v.)
Number of subjects: 127
Study 26713528 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 127
Study 26713528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UTI and Low-dose UTI
Number of subjects: 127
Study 23715170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg per day
Number of subjects: 287
Study 21044330 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 41
Study 21044330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 41
Study 18427971 — intervention group
Group type: COMPARATOR
Intervention: Inactive comparison condition from a randomized HIV prevention trial (Project SHIELD)
Number of subjects: 0
Study 16328283 — intervention group
Group type: EXPERIMENTAL
Intervention: VL thalamotomy
Number of subjects: 10
Study 12478076 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV-1 testing
Number of subjects: 1249
Study 12478076 — intervention group
Group type: COMPARATOR
Intervention: Conventional HIV-1 testing (ELISA)
Number of subjects: 1249
Study 11708572 — intervention group
Group type: EXPERIMENTAL
Intervention: lysine clonixinate 125 mg plus propinox 10 mg
Number of subjects: 125